课题基金 / 基金详情

PATHFINDER: A Pragmatic, Active Comparator, Parallel-Group, Randomized Trial to Evaluate the Optimal First-Line Treatment Strategy for Moderate to Severely Active Ileal Crohn's Disease

PATHFINDER: A Pragmatic, Active Comparator, Parallel-Group, Randomized Trial to Evaluate the Optimal First-Line Treatment Strategy for Moderate to Severely Active Ileal Crohn's Disease
PATHFINDER：一项务实、积极的比较、平行组、随机试验，用于评估中度至重度活动性回肠克罗恩病的最佳一线治疗策略
批准号：
469579
负责人：
Ma Christopher
金额：
$17.83万
依托单位：
University of Calgary
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
已结题
起止时间：
2022-09-01 至 2024-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=469579&lang=en
关键词：
Biologic Crohn'S Disease Endoscopic Remission Inflammatory Bowel Disease Natural History Pilot Pragmatic Probe Randomized Clinical Trial

项目摘要

项目成果

Ma Christopher的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Crohn's disease (CD) is a chronic, life-long, bowel disease without a cure. Most patients with CD have inflammation in the last portion of the small bowel, called the ileum. Patients with inflammation predominantly in the ileum (ileal CD) are at higher ri
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of a Core Outcomes Set for Clinical Trials in Inflammatory Bowel Disease: An International Collaboration
  • 批准号：
    363813
  • 项目类别：
    Fellowship Programs
  • 资助金额：
    $4.01万
  • 财政年份：
    2016
  • 负责人：
    Ma Christopher
  • 依托单位：
    University of Western Ontario
Hospitalization for Inflammatory Bowel Diseases: Risk Factors, Temporal Trends, and Health Care Utilization
  • 批准号：
    182305
  • 项目类别：
    Summer Student Programs
  • 资助金额：
    $0.22万
  • 财政年份：
    2009
  • 负责人：
    Ma Christopher
  • 依托单位：
    University of Calgary
海外基金